Palonozetron Kalceks (Palonosetron)

Palonosetron, the active ingredient in Palonozetron Kalcecks, is a 5‑HT₃ receptor antagonist presented as a strength/form for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonozetron Kalcecks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonozetron Kalcecks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is indicated for prevention of nausea and vomiting associated with chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting (CINV): Reduces the incidence and severity of acute and delayed CINV. - Post‑operative nausea and vomiting (PONV): Decreases the frequency of nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: Helps control symptoms when radiation therapy triggers emesis. - Antiemetic prophylaxis in highly emetogenic regimens: Provides extended protection for patients receiving highly emetogenic chemotherapy protocols.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: Mild to moderate headache reported in clinical studies. - Constipation: Reduced bowel motility leading to occasional constipation. - Fatigue: General feeling of tiredness or lack of energy. - Dizziness: Transient episodes of light‑headedness.

Serious or Rare Side Effects: - QT interval prolongation: May affect cardiac electrical activity, requiring ECG monitoring in susceptible patients. - Severe hypersensitivity: Includes rash, pruritus, bronchospasm, or anaphylaxis. - Serotonin syndrome: Rare but possible when combined with other serotonergic agents. - Cardiac arrhythmias: Uncommon arrhythmic events reported in post‑marketing surveillance.

When using Palonosetron, consider the following safety measures:

- Cardiac monitoring: Assess baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: Review all serotonergic medications to avoid additive effects. - Electrolyte balance: Correct hypokalemia, hypomagnesemia, or hypocalcemia before administration. - Pregnancy and lactation: Use only if the potential benefit justifies the risk. - Renal or hepatic impairment: Adjust monitoring in patients with severe organ dysfunction. - Store at ambient temperature: Keep below 25°C, protect from moisture and light.

Palonosetron may interact with several drug classes.

Major Interactions (Avoid): - QT‑prolonging agents: Co‑administration can increase risk of cardiac arrhythmias. - Potent CYP3A4 inhibitors: May raise palonosetron plasma levels, though clinical relevance is limited.

Moderate Interactions (Monitor Closely): - Other serotonergic agents: May increase risk of serotonin syndrome. - Anticholinergic drugs: May exacerbate constipation. - Diuretics causing electrolyte loss: Heighten risk of QT prolongation. - Anesthetic agents used in surgery: May compound hypotensive effects.